Palvella Therapeutics (NASDAQ:PVLA) Sets New 12-Month High – Should You Buy?

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $151.36 and last traded at $152.2460, with a volume of 245279 shares trading hands. The stock had previously closed at $148.21.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PVLA shares. Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. HC Wainwright increased their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Stephens reaffirmed an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, Chardan Capital reiterated a “buy” rating and set a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Palvella Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Trading Up 4.3%

The business’s 50-day simple moving average is $118.78 and its 200-day simple moving average is $110.27. The company has a market cap of $2.22 billion, a PE ratio of -36.89 and a beta of -0.14.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, research analysts predict that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $238,512.42. This represents a 66.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Several institutional investors have recently made changes to their positions in the company. Group One Trading LLC grew its stake in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares in the last quarter. KBC Group NV acquired a new stake in Palvella Therapeutics in the first quarter valued at approximately $28,000. Price T Rowe Associates Inc. MD grew its position in Palvella Therapeutics by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after acquiring an additional 433 shares in the last quarter. Bank of America Corp DE grew its position in Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after acquiring an additional 515 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Palvella Therapeutics by 8.7% during the 4th quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after purchasing an additional 528 shares during the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.